[Cerebrolysin alleviates perinatal CNS disorders through the autoimmune modulation and antioxidant protection].
We investigated the effects of the neuroprotective drug cerebrolysin on the autoimmune parameters (FasL, Fas and metallotionein-1) in 20 newborns with perinatal ischemic CNS damage and 20 healthy newborns. The treatment with cerebrolysin in dosage of 0,1 ml per 1 kg of body mass, 10 injections every other day, resulted in the normalization (p<0,001) of the T-lymphocyte apoptosis (the increase of Fas and decrease of FasL) and activation of antioxidant protection through the increase of metallotionein-1 expression. The normalization of the autoimmunity was found to reduce edema and improve the circulation of the brain sites affected with ischemia.
Serkina
E V
EV
Gromova
O A
OA
Torshin
I Iu
IIu
Sotnikova
N Iu
NIu
Nikonov
A A
AA
D000596:Amino Acids / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001323:Autoantibodies / Q000276:immunology*; D053222:Fas Ligand Protein / Q000235:genetics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology*; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology*; D007231:Infant, Newborn; D008668:Metallothionein / Q000235:genetics; D018697:Nootropic Agents / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000187:drug effects
D000596:Amino Acids; D000975:Antioxidants; D001323:Autoantibodies; D053222:Fas Ligand Protein; C530099:MT1A protein, human; D018697:Nootropic Agents; C006952:cerebrolysin; D008668:Metallothionein